Biomarin Pharmaceutical INC (BMRN) SEC Filings — 2024
24 SEC filings for Biomarin Pharmaceutical INC (BMRN) in 2024.
Filings
- BioMarin Pharma Q3 Revenue Rises to $590.6M — 10-Q · Oct 31, 2024
- BioMarin Pharmaceutical Inc. Files 8-K — 8-K · Oct 29, 2024
- Biomarin Pharmaceutical INC SC 13G Filing — SC 13G · Sep 30, 2024
- BioMarin Pharmaceutical Inc. Files 8-K for Regulation FD Disclosure — 8-K · Sep 24, 2024
- BioMarin Pharmaceutical Inc. Enters Material Definitive Agreement — 8-K · Sep 4, 2024
- BioMarin Pharmaceutical Inc. Reports Exit/Disposal Costs — 8-K · Aug 28, 2024
- BioMarin Appoints New Chief Medical Officer and Controller — 8-K · Aug 22, 2024
- BioMarin Pharmaceutical Q2 Revenue Edges Up to $620.5M — 10-Q · Aug 5, 2024
- Biomarin Pharmaceutical INC SC 13G/A Filing — SC 13G/A · Jul 10, 2024
- Biomarin Pharmaceutical INC SC 13G/A Filing — SC 13G/A · Jul 8, 2024
- BioMarin Pharmaceutical Inc. Files 8-K on Shareholder Votes — 8-K · May 24, 2024
- BioMarin Reports Exit/Disposal Costs — 8-K · May 14, 2024
- BioMarin Pharmaceutical Inc. Files 10-Q for Q1 2024 — 10-Q · Apr 26, 2024
- BioMarin Pharmaceutical Inc. Files 8-K on Financials — 8-K · Apr 24, 2024
- BioMarin CFO Resigns, Interim Appointed — 8-K · Apr 23, 2024
- BioMarin Pharmaceutical Inc. Files Definitive Proxy Statement — DEF 14A · Apr 9, 2024
- BioMarin Pharmaceutical Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 26, 2024
- BioMarin Files 8-K on Financial Condition and Operations — 8-K · Feb 22, 2024
- Biomarin Pharmaceutical INC SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- Biomarin Pharmaceutical INC SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- PRIMECAP Cuts BioMarin Stake to 9.7%, Still Major Holder — SC 13G/A · Feb 12, 2024
- Capital Research Global Investors Discloses 10.77M Share Stake in BioMarin — SC 13G · Feb 9, 2024
- BlackRock Amends BioMarin Stake, Signals Continued Institutional Interest — SC 13G/A · Jan 26, 2024
- BioMarin 8-K: Executive Compensation Arrangements Updated — 8-K · Jan 11, 2024